New Gut-Restricted Pharmaceutical Compound Shields Liver and Enhances Nutrient Intake Following Intestinal Surgery

WashU Medicine researchers develop a new drug that stays in the gut to protect the liver and boost nutrients. A major breakthrough for short bowel syndrome.

By: AXL Media

Published: Mar 19, 2026, 11:46 AM EDT

Source: Information for this report was sourced from WashU Medicine

Addressing the Collateral Damage of Life Saving Surgery

A significant medical paradox exists for patients requiring the removal of diseased or necrotic sections of the small intestine. While the surgery is often essential for survival, it frequently triggers a secondary and potentially fatal complication: severe liver dysfunction. Approximately 15 percent of patients who undergo this procedure eventually face liver failure, yet there are currently no approved pharmacological treatments to mitigate this risk. This clinical gap has led researchers to investigate the biological link between a shortened gut and the rapid deterioration of liver tissue, seeking a way to protect one organ by treating another.

The Discovery of the Gut Liver Pathogenic Axis

The foundation for this new therapeutic approach stems from a 2021 discovery at WashU Medicine, which identified how substances produced by gut bacteria infiltrate the liver post-surgery. These microbial byproducts trigger inflammatory responses that lead to fibrosis and eventual organ failure. Scientists noted that high-density lipoprotein, or HDL, serves as a natural defense by blocking these harmful substances. By leveraging this biological insight, the team sought to develop a method to boost the body's natural "good" cholesterol production specifically within the digestive system to neutralize toxins before they can reach the hepatic blood supply.

Precision Engineering of a Localized Therapy

To avoid the dangerous side effects associated with previous liver-targeted medications, the research team synthesized a "gut-restricted" version of a liver X receptor agonist. This compound, identified as WUSTL0717, is designed to remain exclusively within the gastrointestinal tract after oral administration rather than entering the general bloodstream. This precision-based strategy allows the drug to stimulate protective HDL production in the intestines without affecting other organ systems. Medicinal chemistry expert Dr. Bahaa Elgendy noted that this approach makes it possible to revisit powerful biological targets that were previously deemed too hazardous for human use due to systemic toxicity.